THYROCARE
vs
BSE Sensex 30

Over the past 5 years, THYROCARE has underperformed BSE Sensex 30, delivering a return of 83% compared to the BSE Sensex 30's 88% growth.

Stocks Performance
THYROCARE vs BSE Sensex 30

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
THYROCARE vs BSE Sensex 30

Performance Comparison
THYROCARE vs BSE Sensex 30

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
THYROCARE
Thyrocare Technologies Ltd
-12%
13%
41%
38%
83%
74%
74%
BSE Sensex 30
Market Index
-3%
-5%
-2%
9%
88%
180%
1 069%

Thyrocare Technologies Ltd
Glance View

Market Cap
48.4B INR
Industry
Health Care

Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.

THYROCARE Intrinsic Value
678.48 INR
Overvaluation 26%
Intrinsic Value
Price

See Also

Back to Top